Type of security: Fund
The data is delayed by 15 minutes.
Description: The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
See how to gain 20% in 14 sec with TrendsInvesting
|High 52 week||122.16||Low 52 week||96.21||Last close||96.21||Last change||-2.14%|
|RSI||23.11||Average true range||3.24||Beta||0.99||Volume||1.25 M|
|Simple moving average 20 days||-7.65%||Simple moving average 50 days||-9.54%||Simple moving average 200 days||-13.16%|
|Performance Week||-8.79%||Performance Month||-8.42%||Performance Quart||-18.21%||Performance Half||-15.41%|
|Performance Year||-9.31%||Performance Year-to-date||-9.76%||Volatility daily||1.62%||Volatility weekly||3.62%|
|Volatility monthly||7.43%||Volatility yearly||25.72%||Relative Volume||180.65%||Average Volume||2.11 M|
|New High||New Low|
|30-day SEC yield||Average market capitalization||Average weighted market capitalization||Forward P/E|
|Gross expense ratio||Index dividend yield||Median market cap||Number of holdings||0|
|Price to Book Value||9.9||Price to Earnings||40.91||Total expense ratio||0.48%||Total net assets||4.92 B|
|Weighted market capitalization|
|Total Expense Ratio||0,48|
|Number Of Holdings||n/a|
|Total Net Assets||4 915 409 116,00|
|Biogen Idec Inc||8,04|
|Gilead Sciences Inc||7,67|
|Alexion Pharmaceuticals Inc||6,78|
|Regeneron Pharmaceuticals Inc||4,04|
|Vertex Pharmaceuticals Inc||3,92|
|Biomarin Pharmaceutical Inc||2,36|
2019-03-21 11:16:40 | Biotech Funds Could Generate Profitable Short Sales
2019-03-21 06:52:00 | Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role
2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-03-14 15:51:00 | Gilead Stock Could Surge to $84, Says Analyst
2019-03-11 12:27:09 | Is iShares Nasdaq Biotechnology Index Fund a Buy?
2019-03-10 14:32:48 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs
2019-03-05 15:32:00 | Biotech stocks turn lower after reports of FDA commissioner resigning
2019-03-05 08:00:00 | CNBC ETF Edge: Biotech Getting Sick?
2019-03-04 13:44:05 | How you should trade the biotech ETFs
2019-03-04 08:39:00 | Nightstar Therapeutics' stock rockets on Biogen buyout deal valued at $877 million
2019-02-27 15:00:32 | 7 of the Best Biotech ETFs
2019-02-20 09:32:02 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-02-14 13:00:06 | Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
2019-02-12 15:21:00 | Anchiano Therapeutics' stock set to close well below its IPO price
2019-02-12 09:29:00 | Anchiano Therapeutics IPO prices below assumed price
2019-02-07 10:49:00 | Alector's stock opens below IPO price, then swings above it
2019-01-29 08:56:10 | Biogen Stock Running in Place Despite Strong Quarter
2019-01-28 15:52:46 | What Are Analysts Recommending for AbbVie after Q4 2018 Results?
2019-01-28 08:52:00 | Amgen downgraded to in-line from outperform by Evercore ISI
2019-01-25 13:36:00 | MacroGenics stock gains 4% after FDA lifts partial clinical hold
2019-01-25 10:02:22 | Intuitive Surgical Stock Dips Are Buying Opportunities
2019-01-25 08:32:00 | NuCana's stock soars after withdrawing ADS offering, which triggered a big selloff
2019-01-24 13:00:06 | What's Behind the Biotech ETF Rally to Start 2019?
2019-01-23 07:51:00 | Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols
2019-01-22 11:06:00 | Editas stock down 21% after announcing CEO departure
2019-01-22 09:17:00 | Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data
2019-01-17 07:13:02 | Trade of the Day: The Biotechnology Stocks ETF Is Running Out of Steam
2019-01-17 07:00:00 | Trending: Investors Turn to Dividend Aristocrats Amid Market Volatility
2019-01-16 12:26:40 | Aptinyx Stock Plunged 70% after Clinical Trial Failure
2019-01-16 09:19:00 | Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint
2019-01-11 10:59:27 | Why Sarepta Therapeutics Stock Is Starting to Shine Again
2019-01-11 08:30:00 | Bear market in value stocks is ending, Wells Fargo predicts a 2019 comeback
2019-01-08 08:00:00 | Two ways to play the biotech boom
2019-01-07 15:02:25 | Three Healthcare Stocks Rallying Over 10% Today
2019-01-07 12:53:00 | ETF Edge, January 7, 2019
2019-01-07 12:26:00 | ETF Edge: Biotech breakout
2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
2019-01-04 07:13:00 | Mersana to discontinue development of one cancer treatment to focus on another
2018-12-31 09:00:22 | Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates